Flucytosine Resistance Is Restricted to a Single Genetic Clade of Candida albicans
Open Access
- 1 January 2004
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (1) , 262-266
- https://doi.org/10.1128/aac.48.1.262-266.2004
Abstract
Population studies have revealed that Candida albicans can be separated into five major clades, groups I, II, III, SA, and E. Groups SA and E are highly prevalent in South Africa and Europe, respectively, while group II is excluded from the southwestern portion of the United State. In each geographical locale, several clades exist side by side, suggesting little interclade recombination. These results suggest clade-specific phenotypes. In the present study we demonstrate that resistance to flucytosine (5FC MIC ≥ 32 μg/ml), an antifungal used for the treatment of systemic C. albicans infections, is restricted to clade I. In addition, while 97% of all strains for which 5FC MICs were ≥0.5 μg per ml were members of group I, only 3% were members of the other groups. 5FC MICs were ≥0.5 μg per ml for 72% of all group I isolates, while 5FC MICs were ≥0.5 μg per ml for only 2% of all non-group I isolates. These results demonstrate for the first time the clade specificity of a clinically relevant trait (5FC resistance) and suggest that while intraclade recombination may be common, interclade recombination is rare.Keywords
This publication has 40 references indexed in Scilit:
- Candida albicanscladesFEMS Immunology & Medical Microbiology, 2003
- Skin Facilitates Candida albicans MatingInfection and Immunity, 2003
- Drug Resistance Is Not Directly Affected by Mating Type Locus Zygosity in Candida albicansAntimicrobial Agents and Chemotherapy, 2003
- Cell Biology of Mating inCandida albicansEukaryotic Cell, 2003
- In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of Candida spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing MethodsAntimicrobial Agents and Chemotherapy, 2002
- Ca3 Fingerprinting of Candida albicans Bloodstream Isolates from the United States, Canada, South America, and Europe Reveals a European CladeJournal of Clinical Microbiology, 2002
- A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemicCandida infections in intensive care patientsInfection, 1996
- Antigenic Variability of Candida AlbicansCRC Critical Reviews in Microbiology, 1985
- Correlation of in Vitro Susceptibility Test Results with in Vivo Response: Flucytosine Therapy in a Systemic Candidiasis ModelThe Journal of Infectious Diseases, 1983
- A Study of 666 Strains of Candida albicans: Correlation between Serotype and Susceptibility to 5-FluorocytosineThe Journal of Infectious Diseases, 1979